Lyra Therapeutics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 27 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $7K | ↓-96.7% | — | — | — |
| 2025-09-30 | $25K | ↓-87.2% | $-6M | ↑+49.6% | -24948.0% |
| 2025-06-30 | $183K | ↓-69.4% | $-7M | ↑+84.5% | -4823.0% |
| 2025-03-31 | $183K | ↓-65.6% | $-9M | ↑+61.9% | -4831.1% |
| 2024-12-31 | $209K | ↑+43.2% | — | — | — |
| 2024-09-30 | $195K | ↓-64.2% | $-12M | ↑+24.1% | -6380.5% |
| 2024-06-30 | $598K | ↑+30.6% | $-48M | ↓-208.2% | -8189.6% |
| 2024-03-31 | $532K | ↑+29.8% | $-22M | ↓-38.1% | -4421.8% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$7K
↓-96.7% -$202K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
LYRA Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyLYRA Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics